BACKGROUND: We assessed the effect of hemodialysis (HD) and chronic kidney disease (CKD) on the serum levels of metalloproteinase-2 (MMP-2), MMP-9 and metalloproteinase tissue inhibitors (TIMP-1) and TIMP-2. METHODS: 18 patients on regular HD treatment with low-flux, cuprophane membrane, 15 non-dialyzed patients with CKD and 15 healthy controls were sampled. The serum MMP and TIMP concentrations were determined by ELISA assays. RESULTS: MMP-9, TIMP-1, and TIMP-2 serum levels were significantly decreased in HD patients to 32.7 ± 20.1 ng/ml, 178.8 ± 73.0 ng/ml, and 103.4 ± 55.3 ng/ml compared with 482.3 ± 139.5, 367.6 ± 75.5 ng/ml, and 299.7 ± 63.2 ng/ml in patients with CKD and 594.6 ± 154.7 ng/ml, 354.5 ± 81.2 ng/ml, and 272.4 ± 91.8 ng/ml in healthy controls, respectively, (P < 0.001 vs. HD patients). MMP-2 was lower in patients with CKD: 405.6 ± 106.1 ng/ml compared with 516.9 ± 81.7 ng/ml in controls (P = 0.02). The MMP-2/TIMP-2 ratio was increased in HD patients compared with both patients with CKD and controls. In the course of an HD session, MMP-2 and TIMP-1 serum levels were significantly decreased from pre-HD 570.0 ± 256.5 and 178.8 ± 66.9 ng/ml to post-HD 492.6 ± 212.5 and 144.6 ± 44.2 ng/ml (P = 0.004 and 0.013, respectively). However, the MMP-9/TIMP-1 ratio increased from pre-HD 0.15 (2.19) (median, range) to 0.23 (0.33) after a HD session (P = 0.03). CRP was positively correlated with MMP-9 and MMP-9/TIMP-1 ratio in HD patients and patients with CKD (r = 0.67; P = 0.03). CONCLUSIONS: The MMP-9/TIMP-1 ratio increased during HD sessions, although their absolute levels were lowered. This change may represent a chronic state of enhanced fibrosis in patients undergoing HD.
BACKGROUND: We assessed the effect of hemodialysis (HD) and chronic kidney disease (CKD) on the serum levels of metalloproteinase-2 (MMP-2), MMP-9 and metalloproteinase tissue inhibitors (TIMP-1) and TIMP-2. METHODS: 18 patients on regular HD treatment with low-flux, cuprophane membrane, 15 non-dialyzed patients with CKD and 15 healthy controls were sampled. The serum MMP and TIMP concentrations were determined by ELISA assays. RESULTS:MMP-9, TIMP-1, and TIMP-2 serum levels were significantly decreased in HDpatients to 32.7 ± 20.1 ng/ml, 178.8 ± 73.0 ng/ml, and 103.4 ± 55.3 ng/ml compared with 482.3 ± 139.5, 367.6 ± 75.5 ng/ml, and 299.7 ± 63.2 ng/ml in patients with CKD and 594.6 ± 154.7 ng/ml, 354.5 ± 81.2 ng/ml, and 272.4 ± 91.8 ng/ml in healthy controls, respectively, (P < 0.001 vs. HDpatients). MMP-2 was lower in patients with CKD: 405.6 ± 106.1 ng/ml compared with 516.9 ± 81.7 ng/ml in controls (P = 0.02). The MMP-2/TIMP-2 ratio was increased in HDpatients compared with both patients with CKD and controls. In the course of an HD session, MMP-2 and TIMP-1 serum levels were significantly decreased from pre-HD 570.0 ± 256.5 and 178.8 ± 66.9 ng/ml to post-HD 492.6 ± 212.5 and 144.6 ± 44.2 ng/ml (P = 0.004 and 0.013, respectively). However, the MMP-9/TIMP-1 ratio increased from pre-HD 0.15 (2.19) (median, range) to 0.23 (0.33) after a HD session (P = 0.03). CRP was positively correlated with MMP-9 and MMP-9/TIMP-1 ratio in HDpatients and patients with CKD (r = 0.67; P = 0.03). CONCLUSIONS: The MMP-9/TIMP-1 ratio increased during HD sessions, although their absolute levels were lowered. This change may represent a chronic state of enhanced fibrosis in patients undergoing HD.
Authors: Jacek Rysz; Maciej Banach; Aleksandra Cialkowska-Rysz; Robert Stolarek; Marcin Barylski; Jaroslaw Drozdz; Piotr Okonski Journal: Cell Mol Immunol Date: 2006-04 Impact factor: 11.530
Authors: Jacek Rysz; Maciej Banach; Robert A Stolarek; Jaroslaw Pasnik; Aleksandra Cialkowska-Rysz; Robert Koktysz; Mariusz Piechota; Zbigniew Baj Journal: J Nephrol Date: 2007 Jul-Aug Impact factor: 3.902
Authors: M Dolores Arenas; Fernando Alvarez-Ude; M Teresa Gil; Antonio Soriano; Juan José Egea; Isabel Millán; M Luisa Amoedo; Salomé Muray; M Antonia Carretón Journal: Nephrol Dial Transplant Date: 2006-02-07 Impact factor: 5.992
Authors: Gloria A Preston; Cheri V Barrett; David A Alcorta; Susan L Hogan; Lesley Dinwiddie; J Charles Jennette; Ronald J Falk Journal: Nephron Date: 2002-12 Impact factor: 2.847
Authors: Jacek Rysz; Maciej Banach; Robert A Stolarek; Jarosław Pasnik; Aleksandra Ciałkowska-Rysz; Leszek Markuszewski; Zbigniew Baj Journal: Arch Immunol Ther Exp (Warsz) Date: 2006-05-31 Impact factor: 4.291
Authors: Barbara Dołęgowska; Wojciech Błogowski; Joanna Stępniewska; Krzysztof Safranow; Katarzyna Jakubowska; Maria Olszewska Journal: Int Urol Nephrol Date: 2011-11-30 Impact factor: 2.370
Authors: Emi E Okamoto; Jacqueline E Sherbuk; Eva H Clark; Morgan A Marks; Omar Gandarilla; Gerson Galdos-Cardenas; Angel Vasquez-Villar; Jeong Choi; Thomas C Crawford; Rose Q Do; Rose Q; Antonio B Fernandez; Rony Colanzi; Jorge Luis Flores-Franco; Robert H Gilman; Caryn Bern Journal: PLoS Negl Trop Dis Date: 2014-10-02
Authors: Anna Gluba-Brzózka; Marta Michalska-Kasiczak; Beata Franczyk-Skóra; Marek Nocuń; Maciej Banach; Jacek Rysz Journal: Lipids Health Dis Date: 2014-08-21 Impact factor: 3.876
Authors: Ashraf Galal; Fatina I Fadel; Enas Mokhtar; Manal F Elshamaa; Eman A Elghoroury; Solaf Kamel; Gamila S M Elsaeed; Eman H Thabet Journal: Int J Biomed Sci Date: 2016-09
Authors: Anna Gluba-Brzózka; Marta Michalska-Kasiczak; Beata Franczyk; Marek Nocuń; Peter Toth; Maciej Banach; Jacek Rysz Journal: Lipids Health Dis Date: 2016-02-03 Impact factor: 3.876